Tempus and Natera are subject to new financial analysis from BNP Paribas and William Blair regarding valuation and strategic fit.

1 report, 1 independent Updated Jul 21

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Tempus Natera

Keep exploring

Part of

Tempus and Natera are operating in the competitive field of ctDNA diagnostics. All 1 developments

The entities involved

Tempus
biotechnology company based in Chicago, Illinois
- Tempus is scheduled to participate in a conference in New York City on September 4, 2025.Sun 01:41
- Tempus AI, led by Eric Lefkofsky, is acquiring Paige to enhance its digital pathology datasets.Sat 00:42
Natera
company in San Carlos, United States
- Natera and Fractyl Health, biotech companies, traded on the NASDAQ stock exchange on September 1, 2026.Mon 02:47
- Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.Sun 02:44

Coverage

Newest first; wire copies grouped

Jul 21benzinga.com